Autosomal dominant polycystic kidney disease, widely known as ADPKD, is a genetic condition in which fluid-filled cysts gradually enlarge both kidneys, eventually impairing their ability to filter blood. It affects roughly one in 400 to one in 1,000 people worldwide, making it one of the most common inherited kidney diseases and a leading genetic cause of kidney failure in adults.1PubMed. MR Angiography Screening and Surveillance for Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Cost-effectiveness Analysis But ADPKD is far from a kidneys-only problem. It can drive cyst growth in the liver, weaken blood vessel walls in the brain, raise blood pressure years before kidney function drops, and interfere with daily life through chronic pain and fatigue. Understanding what drives the disease, how doctors track it, and what treatments can slow it down matters for the roughly half of affected individuals who will eventually need dialysis or a transplant.
What Happens Inside the Kidney
ADPKD starts with mutations in one of two genes, PKD1 or PKD2, which encode proteins called polycystin-1 and polycystin-2. These proteins sit in tiny, antenna-like structures called primary cilia that protrude from kidney-lining cells into the fluid flowing through the kidney’s tubules. In healthy kidneys, the polycystins work together to sense fluid flow and translate that mechanical signal into a calcium response inside the cell. When polycystin-1 or polycystin-2 is missing or dysfunctional, cells lose the ability to detect these flow cues, and that loss of feedback is now understood as a trigger for cyst formation.2Nature Genetics. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells Because of this connection to cilia, ADPKD is classified among the ciliopathy diseases.3PubMed Central. The Roles of Primary cilia in Polycystic Kidney Disease
The downstream consequences go further than a missed calcium signal. Research has shown that the tail end of polycystin-1 can be cleaved and transported into the cell nucleus, where it interacts with a transcription factor called STAT6. In normal cells, this signaling pathway responds to the start and stop of fluid flow. In ADPKD, the pathway becomes inappropriately activated: cyst-lining cells show elevated levels of nuclear STAT6, which drives abnormal gene expression and fuels cyst growth.4PubMed. Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation and is activated in polycystic kidney disease
How Cysts Expand
A cyst does not just passively collect fluid. Cyst-lining cells actively pump chloride into the cyst interior, and water follows. This secretion is driven by a signaling molecule called cyclic AMP (cAMP), which is abnormally elevated in ADPKD cells. The chloride transport itself relies on a channel called CFTR, the same channel that is defective in cystic fibrosis.5PubMed Central. Cyclic AMP-mediated cyst expansion 6PubMed. Targeting chloride transport in autosomal dominant polycystic kidney disease In addition to inflating existing cysts, high cAMP levels also stimulate the cyst-lining cells to divide more rapidly, so cysts both grow larger and multiply. This is why the single approved drug for ADPKD, tolvaptan, was designed to suppress cAMP production in kidney cells.
Why Blood Pressure Rises Early
Hypertension is often the first clinical sign of ADPKD, frequently appearing in a person’s twenties or thirties, well before any noticeable decline in kidney function. The culprit appears to be a renin-angiotensin system operating locally inside the kidneys rather than in the bloodstream. Studies of ADPKD tissue show that cysts produce the components of this system themselves: renin from cysts derived from one type of tubule, and angiotensinogen from cysts of another origin. The result is high concentrations of angiotensin II right inside the kidney, which constricts blood vessels and retains salt.7PubMed. The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease Interestingly, blood tests for these same hormones often look normal, which can make the hypertension seem unexplained. Urinary measurements tell a different story: people with ADPKD excrete about five to six times more angiotensinogen and renin in their urine than healthy controls, reflecting the overactive local system.8PubMed. Urinary renin-angiotensin markers in polycystic kidney disease
This is why blood pressure management is considered a cornerstone of ADPKD care. In the HALT-PKD trials, patients with early-stage disease who were kept at a lower blood pressure target (under 110/75) had slower kidney growth compared with those managed at a standard target, alongside reductions in heart muscle thickening and urinary albumin loss.9PubMed Central. Blood pressure in early autosomal dominant polycystic kidney disease For patients with more advanced disease, an ACE inhibitor alone controlled blood pressure in most cases, and adding a second blocker did not improve kidney function decline.10PubMed Central. Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease
Beyond the Kidneys
ADPKD is a systemic disease. The same genes expressed in kidney tubules are also active in bile ducts, blood vessels, and heart tissue, which means cysts and structural problems can crop up far from the kidneys.
Liver Cysts
Polycystic liver disease is the most common extrarenal manifestation. About three-quarters to four-fifths of adults with ADPKD develop liver cysts, and the prevalence climbs with age.11PubMed Central. Liver manifestations in autosomal dominant polycystic kidney disease (ADPKD) and their impact on quality of life Women tend to develop more severe liver involvement than men, and risk factors for worse polycystic liver include higher body mass index and lower hemoglobin levels.12Journal of Korean Medical Science. Factors Associated With the Development and Severity of Polycystic Liver in Patients With Autosomal Dominant Polycystic Kidney Disease Liver cysts rarely cause liver failure, but a massively enlarged liver can cause discomfort, early fullness after eating, and shortness of breath from upward pressure on the diaphragm.
Brain Aneurysms
Roughly one in ten people with ADPKD has an intracranial aneurysm, a weakened balloon-like bulge in a brain artery. Most of these never rupture, but when they do, the consequences can be devastating. Cost-effectiveness analyses support MR angiography screening every five years for ADPKD patients, with annual follow-up imaging for anyone in whom an aneurysm is detected.13PubMed. MR Angiography Screening and Surveillance for Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Cost-effectiveness Analysis In practice, screening is most often recommended for patients with a family history of aneurysm or subarachnoid hemorrhage, though some centers screen all ADPKD patients.
Heart Problems
Left ventricular hypertrophy, where the heart’s main pumping chamber thickens in response to chronic high blood pressure, is found in over 40% of people with ADPKD.14Scientific Reports. Echocardiographic characteristics of autosomal dominant polycystic kidney disease Mild valve leakage, particularly of the mitral valve, is also common. In one center-based study, more than half of ADPKD patients had some degree of mitral regurgitation, though most cases were classified as mild.15PubMed Central. Cardiac Manifestations in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD): A Single-Center Study Aggressive blood pressure control appears to reduce rates of heart thickening over time.16PubMed Central. Cardiovascular Manifestations and Management in ADPKD
Tracking Progression
Traditional kidney function tests like the estimated glomerular filtration rate (eGFR) can look reassuringly normal for years even while cysts are steadily expanding. The kidneys have so much reserve capacity that significant structural damage accumulates before the filtration rate drops. This is why total kidney volume, measured by MRI or ultrasound, has become a critical prognostic biomarker. For a 40-year-old with preserved kidney function, having kidneys twice the expected size roughly doubles the risk of a major decline in filtration, and having kidneys three times the expected size nearly triples it.17PubMed Central. Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
MRI remains the gold standard for measuring kidney volume, but ultrasound is far cheaper and more accessible. Recent comparisons show that ultrasound-based volume measurements correlate strongly with MRI, with correlation coefficients above 0.9, suggesting ultrasound may be adequate for routine monitoring in many settings.18PubMed Central. Ultrasound versus magnetic resonance imaging for calculating total kidney volume in patients with ADPKD: a real-world data analysis Deep-learning tools are also being developed to automate kidney segmentation from imaging, potentially standardizing how progression risk is classified.19PubMed Central. Automated prognosis of renal function decline in ADPKD patients using deep learning
Tolvaptan and Its Trade-Offs
Tolvaptan is the only drug specifically approved for ADPKD. It works by blocking vasopressin receptors in the kidney, which lowers the cAMP levels that drive both cyst-cell proliferation and fluid secretion. Across the two largest trials, TEMPO 3:4 and REPRISE, tolvaptan slowed the annual decline in kidney function by about one to just over 1.5 points of eGFR per year compared to placebo, with the benefit appearing more pronounced in people with more advanced disease.20PubMed Central. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial 21PubMed Central. Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) In TEMPO 3:4, kidney growth was cut by about half compared to placebo over three years.
A recent study also looked at what happens when patients who have reached late-stage disease (CKD stage 5) either continue or stop tolvaptan. Those who continued on a low dose maintained the same rate of kidney function decline they had before reaching that threshold, while those who stopped saw their decline accelerate significantly.22Kidney International Reports. Clinical Research Kidney Function Trajectories with Tolvaptan in ADPKD Patients with CKD-G5 This suggests the drug’s benefit does not simply disappear once the kidneys are severely impaired.
The downsides of tolvaptan are real. Because the drug blocks water reabsorption, patients produce large volumes of dilute urine and need to drink constantly to avoid dehydration. Thirst, frequent urination, and disrupted sleep are common complaints. The more serious concern is liver toxicity: a small percentage of patients develop elevated liver enzymes, and in rare cases the injury can be severe. Regulatory agencies require monthly liver function monitoring during the initial months of treatment, a schedule that five years of post-marketing safety data support as effective for catching problems early.23PubMed Central. Five years of post-marketing liver safety data from the tolvaptan Risk Evaluation and Mitigation Strategy 24PubMed Central. Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
Can Drinking More Water Replace Tolvaptan?
Because tolvaptan works partly by diluting urine and suppressing vasopressin’s effects, a logical question is whether simply drinking more water could achieve the same thing. The idea has biological plausibility: lowering urine concentration reduces vasopressin signaling, which should lower cAMP. In animal models, the picture was mixed. High water intake slowed disease in rats but had no clear effect in mouse models, suggesting that the water-achievable level of vasopressin suppression may not always be enough.25PubMed Central. Effects of hydration in rats and mice with polycystic kidney disease
A three-year clinical trial put this to a direct test. Patients randomized to a prescribed high water intake did manage to lower their urine concentration compared with those drinking freely, but kidney growth was not significantly different between the two groups.26PubMed. Prescribed Water Intake in Autosomal Dominant Polycystic Kidney Disease A post hoc analysis of the TEMPO trial data offered a possible explanation: for the same drop in urine concentration, tolvaptan produced a much greater reduction in kidney growth than high water intake alone. Tolvaptan also achieves more sustained 24-hour suppression of vasopressin signaling than drinking water can realistically maintain.27PubMed Central. Comparing Effects of Tolvaptan and Instruction to Increase Water Consumption in ADPKD: Post Hoc Analysis of TEMPO 3:4 So while staying well hydrated is reasonable general advice, current evidence does not support water intake as a substitute for drug therapy.
Diet and Lifestyle
Interest in dietary strategies for ADPKD has surged in recent years, particularly around caloric restriction, intermittent fasting, and ketogenic diets. The rationale centers on metabolic reprogramming: ADPKD cells show altered glucose metabolism, and preclinical studies suggest that restricting their energy supply can slow cyst growth. However, clinical evidence remains thin. Expert consensus currently recommends a more conventional approach: maintaining a healthy body weight, keeping sodium intake low, limiting concentrated sweets, and drinking plenty of fluids.28PubMed Central. Polycystic Kidney Disease Diet: What is Known and What is Safe Environmental and lifestyle factors like smoking, alcohol use, and comorbid conditions such as obesity and diabetes can worsen ADPKD outcomes, and these factors partly explain why two siblings with the exact same mutation can have very different disease courses.29Europe PMC. How Does ADPKD Severity Differ Between Family Members?
Pain and Daily Life
Chronic pain is one of the most underappreciated aspects of living with ADPKD. As kidneys and liver enlarge, the stretching of their capsules and compression of surrounding structures creates a background of dull flank or abdominal pain that can persist for years. In one large registry study, dull kidney pain was reported across all stages of the disease, with a marked increase in severity among those approaching kidney failure. Pain disrupted sleep throughout the disease spectrum, and patients with the most advanced disease were far more likely to report that pain “completely” affected their sleep.30Kidney Medicine. Pain and Health-Related Quality of Life in Autosomal Dominant Polycystic Kidney Disease: Results from a National Patient-Powered Registry
Flank pain specifically has been identified as one of the strongest single predictors of reduced quality of life. In a European study, about a third of ADPKD patients reported flank pain, and those who did scored significantly worse on measures of physical functioning, energy, emotional health, and social activity compared with patients without flank pain.31Clinical Kidney Journal. Flank pain has a significant adverse impact on quality of life in ADPKD: the CYSTic-QoL study Managing ADPKD pain is complicated because nonsteroidal anti-inflammatory drugs can harm already-vulnerable kidneys, and opioids carry addiction risk for what is often a lifelong issue. Many centers emphasize multimodal strategies including nerve blocks, physical therapy, and in severe cases, surgical cyst decompression.
ADPKD in Children and Young Adults
Although ADPKD is typically thought of as an adult disease, cysts can appear in childhood, and in rare cases the disease presents very early in life. An international consensus statement recommends that for children at risk of ADPKD (because a parent carries the diagnosis), two clinical paths are equally valid: either regular surveillance for treatable problems like hypertension, or immediate screening with ultrasound to establish the diagnosis. Ultrasound can detect cysts in an at-risk child, and finding one or more is highly suggestive of ADPKD, but a clean ultrasound does not rule it out during childhood because cysts may not yet have formed.32PubMed Central. International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people Genetic testing is recommended for infants with very early or severe onset and for children who develop progressive disease without a known family history.33PubMed Central. ARPKD and early manifestations of ADPKD: the original polycystic kidney disease and phenocopies
Pregnancy With ADPKD
Women with ADPKD can and do have successful pregnancies, but the condition raises the stakes. Compared with healthy controls, pregnant women with ADPKD face higher rates of hypertension, preeclampsia, urinary tract infections, proteinuria, and worsening kidney function during pregnancy. Fetal outcomes, reassuringly, are largely comparable to the general population, with the exception of a modestly higher rate of fetal distress.34Journal of Maternal-Fetal and Neonatal Medicine. Pregnancy outcomes in autosomal dominant polycystic kidney disease: A case-control study The biggest practical concern is blood pressure control: ACE inhibitors and ARBs, the preferred drugs for ADPKD hypertension, are contraindicated during pregnancy because they can cause fetal harm. Women planning a pregnancy need to switch to safer alternatives under close specialist supervision, ideally before conception. Tolvaptan is also not approved for use during pregnancy.
Emerging Therapies
Tolvaptan is unlikely to remain the only pharmacological option for long. Several other drug classes are being actively studied.
Somatostatin analogs such as lanreotide and pasireotide target the bile duct and kidney tubule cells that line cysts, reducing both cell proliferation and fluid secretion. A meta-analysis found that somatostatin analogs significantly reduced total liver volume by about 7% and total kidney volume by about 3% compared with placebo.35PubMed Central. Somatostatin analog therapy in delaying progression of polycystic liver disease: A meta-analysis with trial sequential analysis Lanreotide specifically reduced liver growth by about 6% relative to controls over 120 weeks, and the benefit partially persisted even four months after the last injection.36PubMed. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease Pasireotide, a broader-acting somatostatin analog, has shown similar effects on liver volume and modest kidney volume reductions, though it did not slow the decline in GFR.37PubMed Central. Somatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial These drugs are particularly promising for patients whose dominant symptom is a massively enlarged liver rather than kidney failure.
SGLT2 inhibitors, originally developed for diabetes, are generating interest because ADPKD cells have altered glucose metabolism and impaired cellular housekeeping pathways. Blocking glucose reabsorption in the kidney tubule could theoretically starve cyst cells of fuel while also providing the kidney-protective benefits these drugs have shown in other forms of chronic kidney disease.38Clinical Kidney Journal. Sodium–glucose cotransporter inhibition in polycystic kidney disease: fact or fiction Clinical trials are underway, but results specific to ADPKD have not yet established whether the benefit holds in polycystic kidneys.
When Kidneys Fail and Transplantation
About half of people with ADPKD will reach end-stage kidney disease, typically between ages 50 and 70, though the timeline varies enormously depending on which gene is mutated, the specific variant, and modifiable risk factors. When that happens, the options are dialysis or transplantation. Kidney transplantation generally offers better long-term survival and quality of life than dialysis, and ADPKD patients tend to do well after transplant.
A unique surgical question in ADPKD is what to do with the native polycystic kidneys. They can be enormous, sometimes weighing several kilograms each, and they can continue to cause pain, bleeding, or infections even after a transplant provides adequate kidney function. Some patients undergo native nephrectomy before transplantation, some at the same time as the transplant, and some afterward. One observational study found that pre-transplant removal of polycystic kidneys was associated with better patient and graft survival at one and five years, particularly when cyst-related urinary tract infections were the driving indication.39PubMed Central. Native nephrectomy in polycystic kidney disease patients on transplant lists: how and when? However, other analyses found no significant difference in patient or graft survival based on whether or when native kidneys were removed.40PubMed Central. Native Nephrectomy in Renal Transplant Recipients With Autosomal-Dominant Polycystic Kidney Disease The decision remains individualized, weighing kidney size, symptom burden, and infection history.
Why Siblings Can Have Very Different Outcomes
One of the most frustrating aspects of ADPKD for families is watching the disease behave differently in relatives who carry the same mutation. One sibling might reach kidney failure in their forties while another retains reasonable function into their sixties. Part of this variability is biological: in a small number of families, one member inherits a second, separate mutation in a cyst-related gene, creating a “double hit” that accelerates disease. But most of the difference comes from more mundane factors. Diet, body weight, smoking, salt intake, blood pressure control, and the presence of comorbid conditions like diabetes or kidney stones all push disease trajectory in different directions.41Europe PMC. How Does ADPKD Severity Differ Between Family Members? This is actually encouraging news, because it means that a meaningful portion of the disease’s severity is modifiable. The genetic mutation sets the stage, but what you do with diet, blood pressure, and lifestyle choices genuinely changes how the disease plays out over decades.